Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. Its clinical course varies widely: while some patients live with stable disease for many years, others experience aggressive progression and early relapse. Despite major advances in targeted therapies, it remains difficult to predict which patients will respond well to treatment and who is at higher risk of disease progression.

This project aims to better understand these differences by studying gene activity in CLL cells. Using modern sequencing technologies and data from large clinical trials, we will identify gene expression patterns associated with treatment response, disease progression and survival. Based on these findings, the scientists will develop a focused gene panel that can be measured with a clinically practical method.

The goal is to create a diagnostic tool that helps identify high-risk disease early and supports more personalized treatment decisions, ultimately improving outcomes and quality of life for people with CLL.